Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S. provides expert guidance and practical know-how for lawyers working in this burgeoning area of the law. This is your opportunity to meet the authors who contributed to this comprehensive guide and go-to reference for all things biosimilars.
Q&A with March’s Featured Author: Alison Siedor
Alison Siedor is an Associate in the firm’s New York office.
What made you want to contribute to the Guide?
Biosimilars have the potential to have a great impact on healthcare, and that makes them very interesting to me. Researching and drafting a section of the Guide seemed like a great way to learn more about this field.
What do you hope people learn from the Guide?
I hope it is helpful as a go-to source for anything someone wanted to know about biosimilar litigation. Previously, comprehensive information about biosimilars was scattered and not easily accessible. So I hope having all the information concisely represented in a single book is helpful to anyone working in the field.
What did you learn from working on the Guide?
How much there still is to learn! We’re still waiting for clear decisions from the courts about some key biosimilar issues, and because of this there’s still some uncertainty in the field. I’m looking forward to continuing to learn as the field develops.
Feel free to contact the authors should you have questions or wish to discuss any topics covered in the Guide or on Big Molecule Watch.
Alison Siedor: asiedor@goodwinlaw.com